Duopharma Biotech Berhad Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Duopharma Biotech Berhad wird ein jährliches Gewinn- und Umsatzwachstum von 24.8% bzw. 8.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 26.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 11.8% betragen.

Wichtige Informationen

24.9%

Wachstumsrate der Gewinne

25.9%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	16.5%
Wachstumsrate der Einnahmen	8.3%
Zukünftige Eigenkapitalrendite	11.9%
Analystenabdeckung	Low
Zuletzt aktualisiert	21 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005

Aug 27

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018

Apr 04

Duopharma Biotech Berhad's (KLSE:DPHARMA) Intrinsic Value Is Potentially 24% Below Its Share Price

Feb 17

These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively

Oct 21

Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005

Aug 18

Calculating The Intrinsic Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Aug 07

Duopharma Biotech Berhad's (KLSE:DPHARMA) Shareholders Will Receive A Smaller Dividend Than Last Year

Mar 28

Calculating The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Mar 27

We Think That There Are Issues Underlying Duopharma Biotech Berhad's (KLSE:DPHARMA) Earnings

Nov 26

Need To Know: The Consensus Just Cut Its Duopharma Biotech Berhad (KLSE:DPHARMA) Estimates For 2021

Nov 25

Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be RM0.005

Aug 20

Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly

May 22

Duopharma Biotech Berhad (KLSE:DPHARMA) Investors Should Think About This Before Buying It For Its Dividend

Apr 13

Is Duopharma Biotech Berhad (KLSE:DPHARMA) The Right Choice For A Smart Dividend Investor?

Jan 12

Gewinn- und Umsatzwachstumsprognosen

KLSE:DPHARMA - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (MYR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	880	99	88	123	4
12/31/2025	826	91	72	112	5
12/31/2024	768	76	79	122	5
3/31/2024	697	45	40	70	N/A
12/31/2023	705	53	9	49	N/A
9/30/2023	689	61	-10	40	N/A
6/30/2023	697	69	-17	35	N/A
3/31/2023	711	72	-32	29	N/A
12/31/2022	697	70	-1	70	N/A
9/30/2022	690	69	21	84	N/A
6/30/2022	685	69	-33	48	N/A
3/31/2022	659	68	-49	63	N/A
12/31/2021	639	66	-72	43	N/A
9/30/2021	628	66	-117	7	N/A
6/30/2021	590	63	-51	58	N/A
3/31/2021	578	63	-21	59	N/A
12/31/2020	570	59	6	71	N/A
9/30/2020	574	54	45	110	N/A
6/30/2020	583	55	37	97	N/A
3/31/2020	585	54	35	96	N/A
12/31/2019	576	55	6	67	N/A
9/30/2019	554	58	-9	63	N/A
6/30/2019	537	55	-5	87	N/A
3/31/2019	516	51	-7	78	N/A
12/31/2018	499	48	-20	72	N/A
9/30/2018	495	45	-33	51	N/A
6/30/2018	485	44	-31	49	N/A
3/31/2018	478	44	-44	34	N/A
12/31/2017	468	42	N/A	56	N/A
9/30/2017	430	39	N/A	38	N/A
6/30/2017	395	34	N/A	20	N/A
3/31/2017	357	29	N/A	25	N/A
12/31/2016	313	27	N/A	33	N/A
9/30/2016	327	31	N/A	50	N/A
6/30/2016	326	33	N/A	56	N/A
3/31/2016	304	35	N/A	-60	N/A
12/31/2015	270	36	N/A	-51	N/A
9/30/2015	232	34	N/A	-53	N/A
6/30/2015	198	34	N/A	-59	N/A
3/31/2015	182	36	N/A	49	N/A
12/31/2014	177	35	N/A	36	N/A
9/30/2014	172	33	N/A	27	N/A
6/30/2014	168	31	N/A	28	N/A
3/31/2014	165	34	N/A	39	N/A
12/31/2013	162	32	N/A	40	N/A
9/30/2013	152	30	N/A	44	N/A
6/30/2013	141	30	N/A	38	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: DPHARMADas prognostizierte Gewinnwachstum (24.8% pro Jahr) liegt über der Sparquote (3.6%).

Ertrag vs. Markt: DPHARMADie Erträge des Unternehmens (24.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt MY (12.4% pro Jahr).

Hohe Wachstumserträge: DPHARMAEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: DPHARMADie Einnahmen des Unternehmens (8.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt MY (6.1% pro Jahr).

Hohe Wachstumseinnahmen: DPHARMADie Einnahmen des Unternehmens (8.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: DPHARMADie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (11.8%).

Duopharma Biotech Berhad Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 11%

Price target decreased by 8.3% to RM1.63

Price target increased to RM1.81

Price target decreased to RM1.97

Price target decreased to RM3.10

Price target raised to RM2.45

Recent updates

Duopharma Biotech Berhad Announces Retirement of Tan Sri, Datin Paduka Siti Sa'diah Binti Sh Bakir as Non-Independent and Non-Executive Chairman

New minor risk - Profit margin trend

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Duopharma Biotech Berhad, Annual General Meeting, Jun 06, 2024

Duopharma Biotech Berhad Announces the Resignation of Puan Amizar Binti Mizuar as Non Independent and Non Executive Director

Consensus EPS estimates fall by 11%

Upcoming dividend of RM0.018 per share

Full year 2023 earnings released: EPS: RM0.055 (vs RM0.074 in FY 2022)

Now 20% undervalued

Third quarter 2023 earnings released: EPS: RM0.009 (vs RM0.017 in 3Q 2022)

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005

Price target decreased by 8.3% to RM1.63

Second quarter 2023 earnings released: EPS: RM0.013 (vs RM0.017 in 2Q 2022)

Duopharma Biotech Berhad Declares Interim Dividend for the 30 June 2023, Payable on 22 September 2023

Duopharma Biotech Berhad Appoints ENCIK MUHAMMAD SHUKRI BIN ISMAIL as Non Independent and Non Executive Alternate Director

Duopharma Biotech Berhad Announces Re-Designation of Dato' Eisah Binti A. Rahman, Member of Nomination and Remuneration Committee as Independent and Non-Executive Chairman of Nomination and Remuneration Committee, Date of Change 1 June 2023

Duopharma Biotech Berhad Announces Retirement of Dato' Mohamad Kamarudin Bin Hassan as Independent and Non-Executive Member of Risk Committee

Full year 2022 earnings: EPS and revenues miss analyst expectations

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018

Upcoming dividend of RM0.018 per share at 1.5% yield

Full year 2022 earnings released: EPS: RM0.074 (vs RM0.071 in FY 2021)

Duopharma Biotech Berhad's (KLSE:DPHARMA) Intrinsic Value Is Potentially 24% Below Its Share Price

Price target increased to RM1.81

Insufficient new directors

Third quarter 2022 earnings released: EPS: RM0.017 (vs RM0.018 in 3Q 2021)

Insufficient new directors

These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively

Insufficient new directors

Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005

Second quarter 2022 earnings released: EPS: RM0.017 (vs RM0.016 in 2Q 2021)

Duopharma Biotech Berhad Announces an Interim Dividend, Payable on 14 September 2022

Calculating The Intrinsic Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Investor sentiment improved over the past week

Now 21% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Duopharma Biotech Berhad, Annual General Meeting, Jun 21, 2022

Now 21% undervalued after recent price drop

Full year 2021 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of RM0.018 per share

Duopharma Biotech Berhad's (KLSE:DPHARMA) Shareholders Will Receive A Smaller Dividend Than Last Year

Calculating The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Full year 2021 earnings: EPS and revenues miss analyst expectations

Duopharma Biotech Declares Second Interim Dividend in Respect of the Financial Year Ended 31 December 2021

We Think That There Are Issues Underlying Duopharma Biotech Berhad's (KLSE:DPHARMA) Earnings

Need To Know: The Consensus Just Cut Its Duopharma Biotech Berhad (KLSE:DPHARMA) Estimates For 2021

Price target decreased to RM1.97

Third quarter 2021 earnings released: EPS RM0.018 (vs RM0.015 in 3Q 2020)

Investor sentiment deteriorated over the past week

Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be RM0.005

Second quarter 2021 earnings released: EPS RM0.022 (vs RM0.022 in 2Q 2020)

Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly

Full year 2020 earnings released: EPS RM0.085 (vs RM0.082 in FY 2019)

Upcoming dividend of RM0.06 per share

Duopharma Biotech Berhad (KLSE:DPHARMA) Investors Should Think About This Before Buying It For Its Dividend

Price target decreased to RM3.10

A Look At The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Investor sentiment deteriorated over the past week

New 90-day low: RM3.03

Full year 2020 earnings released: EPS RM0.085 (vs RM0.082 in FY 2019)

Revenue behind estimates

Duopharma Biotech Berhad (KLSE:DPHARMA) Seems To Use Debt Quite Sensibly

Do Institutions Own Duopharma Biotech Berhad (KLSE:DPHARMA) Shares?

Is Duopharma Biotech Berhad (KLSE:DPHARMA) The Right Choice For A Smart Dividend Investor?

Price target raised to RM2.45

Government of Malaysia, Biocon Sdn. Bhd. and Duopharma Biotech Berhad Extends the Contract Period Under the Agreement One Year Effective from 2 December 2020 Until 1 December 2021

Duopharma Biotech Berhad Announces Temporary Closure of Registered Office

First half earnings released

New 90-day high - RM3.29

Gewinn- und Umsatzwachstumsprognosen